Last updated: December 23, 2024
Sponsor: Amryt Pharma
Overall Status: Active - Recruiting
Phase
4
Condition
N/ATreatment
Metreleptin
Clinical Study ID
NCT06484868
APL-22
2022-502950-14-00
Ages > 12 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Confirmed diagnosis of familial or acquired partial lipodystrophy
Exclusion
Exclusion Criteria:
- Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5times the terminal half-life of the corresponding IMP, whichever is longer, beforethe screening visit.
Other protocol defined inclusion/exclusion criteria apply
Study Design
Total Participants: 12
Treatment Group(s): 1
Primary Treatment: Metreleptin
Phase: 4
Study Start date:
February 08, 2024
Estimated Completion Date:
September 30, 2027
Connect with a study center
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
Lille,
FranceActive - Recruiting
Hopital Pitie-Salpetriere
Paris,
FranceActive - Recruiting
Hôpital Saint-Antoine
Paris,
FranceActive - Recruiting
Centre Hospitalier Lyon-Sud
Pierre-Bénite,
FranceActive - Recruiting
Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
Berlin,
GermanyActive - Recruiting
Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin
Ulm,
GermanySite Not Available
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna,
ItalyActive - Recruiting
Universitá degli Studi "Magna Graecia" di Catanzaro
Catanzaro,
ItalySite Not Available
Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
Novara,
ItalyActive - Recruiting
Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello
Pisa,
ItalyActive - Recruiting
A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia
Udine,
ItalyActive - Recruiting
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
Cambridge,
United KingdomSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.